Developing the Best In Class Treatments

Our mission is to improve the lives of patients by developing novel, best-in-class treatments to address some of the most important unmet patient needs. We aim to develop patient-focused solutions by applying our innovative science and technologies with well-known pharmacology.

SUSTOL, CINVANTI, ZYNRELEF, and our investigational product candidates utilize our innovative formulation science and technology platforms, including our proprietary Biochronomer^® drug delivery technology, which can deliver therapeutic levels of a wide range of otherwise short-acting pharmacological agents over a longer period of time with a single injection or application.

Redefining Acute Care

In a radically changing healthcare environment, we are applying our innovative science and technologies to provide patients and healthcare providers with better ways to reduce postoperative pain and prevent postoperative nausea and vomiting.

With extensive experience in the acute care setting, we are focused on improving the standard of care to address the most critical public health needs, improve patient outcomes, reduce healthcare costs, and deliver medicines that make a difference.

Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle

SAN DIEGO, July 2, 2024 /PRNewswire/ — Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the FDA acknowledged the receipt of the Company’s Prior Approval Supplement (“PAS”) application for ZYNRELEF^® (bupivacaine and meloxicam) extended-release solution VAN. The FDA has assigned a PDUFA goal date of September 23, 2024.

Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN")

SAN DIEGO, May 29, 2024 /PRNewswire/ — Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced the Prior Approval Supplement (“PAS”) submission to the U.S. Food and Drug Administration (“FDA”) for ZYNRELEF^® (bupivacaine and meloxicam) extended-release solution Vial Access Needle (“VAN”).

Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates

Net Product Sales of $34.7 million, which increased from $29.6 million for the same period in 2023. Net Loss Per Share $(0.02), which decreased from $(0.27) for the same period in 2023.

Launched partnership with CrossLink Life Sciences, LLC to expand ZYNRELEF^® promotional efforts in the first quarter of 2024.

Featured Products

SUSTOL^® (granisetron) extended-release injection is a serotonin-3 (5-HT₃) receptor antagonist that is approved by the U.S. Food and Drug Administration (FDA) and is indicated in combination with other antiemetics in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. To learn more, visit sustol.com.

ZYNRELEF® (bupivacaine and meloxicam) extended-release solution is approved in adults for instillation to produce postsurgical analgesia for up to 72 hours after soft tissue and orthopedic surgical procedures including foot and ankle, and other procedures in which direct exposure to articular cartilage is avoided.

CINVANTI^® (aprepitant) injectable emulsion, for intravenous use is a substance P/neurokinin-1 (NK₁) receptor antagonist that is approved by the FDA and is indicated in adults, in combination with other antiemetic agents, for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin and nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC) as a single-dose regimen; and nausea and vomiting associated with the initial and repeat courses of MEC as a 3-day regimen.

Looking to stand out from the crowd during your job search? Click below to gain access to our top tips & tools for candidates during the hiring process!

Recruiting Done Differently.

Improving lives by uniting great people with great companies.

Sign up for our Monthly Newsletter

We’re committed to sharing up-to-date industry insights, our newest career opportunities, and valuable tools to support you throughout your next job search. Let’s stay connected!